Healthcare costs of congenital cytomegalovirus (cCMV) disease in infants during the first two years of life: a retrospective German claims database analysis

Table 3 All-cause healthcare costs^a during the first 366–730 days of life

Cost domain	cCMV₉₀ cohort	“Representative” controls	Mean difference (CI)	p-value^b	cCMV_21-S cohort	“Healthy” controls	Mean difference (CI)	p-value^b
N (infants)	34	2040			15	900
Outpatient
Sum	22,386	935,556			9295	331,279
Mean	658	459	200 (75–325)	< 0.01	620	368	252 (124–379)	< 0.01
SD	369	351			251	179
Min	235	0			235	0
Q1	400	313			470	265
Median	622	414			654	350
Q3	792	533			774	444
Max	2179	9199			1100	2186
Inpatient
Sum	74,440	860,412			39,097	163,295
Mean	2189	422	1768 (− 114 to 3650)	< 0.01	2606	181	2425 (− 1473 to 6323)	< 0.01
SD	5580	3509			7702	724
Min	0	0			0	0
Q1	0	0			0	0
Median	452	0			485	0
Q3	1841	0			1325	0
Max	30,335	144,020			30,335	7505
Pharmaceuticals
Sum	3549	244,180			1052	47,250
Mean	104	120	− 15 (− 74 to 43)	0.88	70	53	18 (− 19 to 55)	0.17
SD	146	741			73	78
Min	0	0			0	0
Q1	27	24			25	11
Median	50	51			40	32
Q3	95	101			92	66
Max	654	28,763			260	1199
Aids and remedies^c
Sum	46,714	268,237			21,266	87604
Mean	1374	131	1242 (232–2253)	0.46	1418	97	1320 (− 97 to 2738)	0.21
SD	3005	988			2794	1576
Min	0	0			0	0
Q1	0	0			0	0
Median	0	0			0	0
Q3	1374	131			1418	97
Max	12,669	27,166			9002	47,207
Total
Sum	147,089	2,308,385			70,711	629,428
Mean	4326	1132	3195 (546–5844)	< 0.01	4714	699	4015 (− 1091 to 9121)	< 0.01
SD	7860	4432			10,087	1904
Min	253	0			253	7
Q1	618	404			993	323
Median	1464	562			1977	441
Q3	3728	809			2537	605
Max	40,384	159,540			40,384	52,518

cCMV congenital cytomegalovirus, cCMV₉₀ infants with cCMV diagnosis during the first 90 days of life, “Representative” infants with no cCMV or CMV diagnosis in the observation period, cCMV_21-S infants with inpatient cCMV diagnosis and symptoms during the first 21 days of life, “Healthy” infants with no ICD-10-GM diagnosis (except Z-diagnoses) until 4th preventive health checkup and no cCMV or CMV diagnosis in the observation period, CI 95% confidence interval, SD standard deviation, Min minimum, Q1 25th percentile, Q3 75th percentile, Max maximum
^aCosts are displayed in Euros (€). Figures were commercially rounded, which may result in minor calculation differences
^bP-value < 0.05 was considered as statistically significant (Wilcoxon rank-sum test)
^cData for aids and remedies were not completely available for all individuals in the database (20.6% cCMV₉₀ cohort and 34.0% respective controls, 20.0% cCMV_21-S cohort and 33.0% respective controls), and single imputation was applied using the mean costs of infants with available data

ISSN: 1478-7547